Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Aug 23;10(10):1829–1838. doi: 10.1158/1535-7163.MCT-11-0206

Figure 4.

Figure 4

Study of the tumor initiation ability of CD133+ cells, a hallmark of tumor stem cells. Groups of nude mice (4–8/group) were injected in the flank with CD133-enriched cells. CD133+ cells were enriched from cultured UMSCC-11B cells using magnetic bead separation. These had the highest tumor incidence and rate of growth. Another group received cells treated with dCD133KDEL prior to implantation. These had the lowest incidence and lowest growth rate. The controls received unsorted tumor cells that were either untreated or pre-treated with an irrelevant control targeted toxin, CD3CD3KDEL. All groups received 300,000 cells. The plot shows the tumor growth rate over time and the table within the figure shows the tumor incidence. The mean tumor volume of the CD133+ sorted group is statistically different than the control group and the dCD133-depleted group using the student T tests (p< 0.0045 and 0.0012, respectively).